title: Cancer immunotherapy targeting survivin: commentary re: V. Pisarev et al., full-length dominant-negative survivin for cancer immunotherapy. Clin. Cancer Res., 9:6523-6533, 2003.
authors.affiliation: The Burnham Institute, La Jolla, California 92037, USA. reedoffice@burnham.org
authors.forename: John C
authors.initials: JC
authors.lastname: Reed
authors.forename: Darcy B
authors.initials: DB
authors.lastname: Wilson
mesh_terms: D000818:Animals; D017951:Antigen Presentation; D005799:Genes, Dominant; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D051034:Inhibitor of Apoptosis Proteins; D051379:Mice; D008869:Microtubule-Associated Proteins / Q000737:chemistry* / Q000235:genetics; D008954:Models, Biological; D009363:Neoplasm Proteins; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D000077022:Survivin
chemical_list: C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D000077022:Survivin